Figure 5. AAV expression in the spinal cord. (A)Schematic of the virus injection paradigm. (B) Time course of spinal EGFP mRNA expression determined by regular PCR (upper panel) and quantified by qPCR (lower panel) (n=4). *p<0.05, **p<0.01 compared to week 1. (C) Distribution of AAV EGFP in the spinal cord determined by immunohistochemistry using an anti-GFP antibody. An anti-beta3-Tubulin antibody was used for staining neurons.